Renal Impairment Clinical Trial
Official title:
A Phase I Study Of The Safety, Pharmacokinetics, And Hematological Activity Of AMD3100 (240 µg/kg) In Subjects With Renal Impairment
Verified date | February 2014 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Eligible male and female subjects with renal impairment (aged 18-78 years) and healthy
control subjects (aged 35 to 78 years) will be enrolled in the study. Subjects with renal
impairment will be enrolled and entered into three groups based on their renal function:
Mild Impairment, Moderate Impairment, and Severe Impairment(not requiring dialysis). Control
subjects will have normal renal function.
The screening visits will occur within 14 days prior to plerixafor administration on study
day one. Subjects will be monitored for 10 hours following administration of the study drug.
In addition, subjects will return to the clinic at 24 and 48 hours after plerixafor
administration for blood samples and safety assessments.
Status | Completed |
Enrollment | 23 |
Est. completion date | August 2007 |
Est. primary completion date | August 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 78 Years |
Eligibility |
Inclusion Criteria: - Signed patient informed consent form prior to any study procedures at Screening. - Subject has not consumed alcohol in the 48 hours prior to the administration of study drug. - Subject agrees to refrain from consumption of alcohol for the duration of the trial. - Subject agrees to practice an approved method of contraception for the duration of the study. - White blood cell count ?3.5*10^9/L. - Absolute polymorphonuclear leukocyte count >2.5*10^9/L. - Platelet count >125*10^9/L. - Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and total bilirubin <2 times upper limit of normal (ULN). - Negative for Human Immunodeficiency Virus (HIV). - Age: Renal impairment subjects, 18-78 years. Control subjects, 35-78 years. - Creatinine clearance measured from 24-hour urine collection (CLcr u): Renal impairment cohorts, Mild Impairment (CLcr u = 51-80 ml/min), Moderate Impairment (CLcr u = 31-50 ml/min), and Severe Impairment (CLcr u <31 ml/min, not requiring dialysis). Control subjects, CLcr u >90 ml/min. Exclusion Criteria: - Known sensitivity to plerixafor or any of its components. - Pregnant or breast-feeding. - Actual body weight exceeds 175% of ideal body mass index. - Subjects judged by the investigator to be at significant risk of failing to comply with the requirements of the protocol. - Any subject who has started new medication within 14 days prior to study drug administration. - Treatment with an investigational product within 30 days prior to trial entry. - Any significant untreated or newly diagnosed medical condition other than renal impairment that in the opinion of the investigator may interfere with the conduct of the study. - Abnormal electrocardiogram with clinically significant rhythm disturbance,(ventricular arrhythmias), or other conduction abnormality that in the opinion of the investigator warrants exclusion of the subject from the trial. - History of clinically significant thrombocytopenia. - Received blood transfusions within 30 days prior to trial entry. - Any subject who requires therapeutic intervention within the 30 days prior to administration of study medication in order to meet the inclusion/exclusion criteria. - Active malignant/neoplastic disease requiring treatment of any kind. - Active infection requiring antibiotics - Renal impairment requiring any method of dialysis - History of kidney transplant - Subjects having clinical status or laboratory parameter deterioration between the time of enrollment and dosing with plerixafor (such that they no longer meet entry criteria) may be removed from the study at the discretion of the treating physician, principal investigator, or sponsor. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Creighton University Medical Center | Omaha | Nebraska |
United States | Apex Research of Riverside | Santa Ana | California |
United States | Prism Research, 1000 Westgate Dr. suite 149 | St. Paul | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose-Normalized Maximum Concentration of Plerixafor (Cmax) | Evaluation of Cmax following a single dose of 240 µg/kg plerixafor administered on Day 1. Cmax was normalized by dose. | Pre-dose of plerixafor to 24 hours post-plerixafor | No |
Primary | Dose-Normalized Area Under the Plerixafor Concentration Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24h) | Evaluation of AUC0-24 hour following a single dose of 240 µg/kg plerixafor administered on Day 1. AUC0-24 was normalized by dose. | Pre-dose of plerixafor to 24 hours post-plerixafor | No |
Secondary | Change From Baseline in Absolute CD34+ Cell Counts at Day 2 | Change in circulating CD34+ cells from baseline to Day 2 (24 hours post-plerixafor) following a single dose of plerixafor. Change from baseline = CD34+ cell count at 24 hours post dose - CD34+ cell count at Baseline. | Baseline, Day 2 | No |
Secondary | Change From Baseline in Absolute White Blood Cell (WBC) Counts at Day 2 | Change in absolute white blood cells from baseline to Day 2 (24 hours post-plerixafor) following a single dose of plerixafor. Change from baseline = absolute white blood cells at 24 hours post dose - absolute white blood cells at Baseline. | Baseline and Day 2 | No |
Secondary | Number of Participants in Overall Safety Summary of Adverse Events (TEAE) | Number of participants with adverse events (AEs) collected from Day 1 (post plerixafor administration) to Day 3. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe, life-threatening) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related'). | up to Day 3 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01937975 -
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
|
Phase 1 | |
Completed |
NCT03284164 -
Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex
|
Phase 1 | |
Completed |
NCT05992155 -
A Study of TAK-279 in Adults With or Without Kidney Problems
|
Phase 1 | |
Completed |
NCT05004311 -
The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics
|
Phase 1 | |
Completed |
NCT04963738 -
A Study of JNJ-73763989 in Adult Participants With Renal Impairment
|
Phase 1 | |
Terminated |
NCT02508740 -
Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
|
Phase 1 | |
Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
Terminated |
NCT00984113 -
Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment
|
Phase 1 | |
Completed |
NCT00750620 -
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
|
Phase 1 | |
Completed |
NCT00842868 -
The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases
|
N/A | |
Completed |
NCT00499187 -
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
|
Phase 4 | |
Completed |
NCT01331941 -
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
|
Phase 1 | |
Completed |
NCT05489614 -
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
|
Phase 1 | |
Completed |
NCT03259087 -
Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)
|
Phase 1 | |
Completed |
NCT05086107 -
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
|
Phase 1 | |
Recruiting |
NCT05349851 -
Bowel Cleansing With Renal Impairment
|
||
Completed |
NCT03660241 -
A Renal Impairment Study for PF-04965842
|
Phase 1 | |
Recruiting |
NCT06037031 -
A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function
|
Phase 1 | |
Completed |
NCT03289208 -
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
|
Phase 1 | |
Completed |
NCT02942810 -
To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment
|
Phase 1 |